Roth Capital Has Pessimistic Outlook of Accuray Q3 Earnings

Accuray Incorporated (NASDAQ:ARAY - Free Report) - Equities researchers at Roth Capital reduced their Q3 2025 earnings estimates for Accuray in a research report issued on Wednesday, February 12th. Roth Capital analyst J. Wittes now expects that the medical equipment provider will post earnings of ($0.05) per share for the quarter, down from their prior estimate of $0.01. The consensus estimate for Accuray's current full-year earnings is $0.01 per share. Roth Capital also issued estimates for Accuray's Q4 2025 earnings at $0.08 EPS.

Accuray (NASDAQ:ARAY - Get Free Report) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.02 EPS for the quarter, topping analysts' consensus estimates of ($0.01) by $0.03. Accuray had a negative net margin of 0.96% and a negative return on equity of 9.75%.

Separately, StockNews.com cut shares of Accuray from a "buy" rating to a "hold" rating in a research note on Tuesday.

Accuray Stock Performance

Shares of ARAY stock remained flat at $2.23 on Friday. 619,188 shares of the stock were exchanged, compared to its average volume of 794,996. The company has a market cap of $229.31 million, a P/E ratio of -44.60 and a beta of 1.51. The firm has a 50-day moving average of $2.14 and a 200-day moving average of $1.99. The company has a debt-to-equity ratio of 3.51, a quick ratio of 0.87 and a current ratio of 1.62. Accuray has a twelve month low of $1.40 and a twelve month high of $2.95.

Institutional Trading of Accuray

Several large investors have recently bought and sold shares of ARAY. Foundry Partners LLC boosted its holdings in Accuray by 51.3% in the 3rd quarter. Foundry Partners LLC now owns 2,187,160 shares of the medical equipment provider's stock valued at $3,937,000 after purchasing an additional 741,900 shares during the last quarter. State Street Corp boosted its holdings in Accuray by 3.8% in the 3rd quarter. State Street Corp now owns 1,894,287 shares of the medical equipment provider's stock valued at $3,410,000 after purchasing an additional 70,008 shares during the last quarter. Barclays PLC boosted its holdings in Accuray by 97.9% in the 3rd quarter. Barclays PLC now owns 210,819 shares of the medical equipment provider's stock valued at $380,000 after purchasing an additional 104,310 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in Accuray by 1,650.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 146,384 shares of the medical equipment provider's stock valued at $263,000 after purchasing an additional 138,022 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Accuray by 489.1% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 277,859 shares of the medical equipment provider's stock valued at $500,000 after purchasing an additional 230,695 shares during the last quarter. Hedge funds and other institutional investors own 64.08% of the company's stock.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.